Insider Analysis From Datamonitor: Increasing Investment In Emerging Markets Shifts Licensing And Deals Focus To Opportunities In Asia-Pacific
This article was originally published in PharmAsia News
By Erin Brady, Datamonitor
You may also be interested in...
India's Health Minister Hits Out At Buyouts By Foreign Drug Makers; Are Investment Restrictions In The Cards?
MUMBAI - India's health minister Ghulam Nabi Azad has reiterated his concerns about the growing dominance of multinational companies in the Indian market, pressing the commerce ministry to disallow full or majority ownership of Indian companies by large foreign drug makers
MUMBAI - Months of widespread speculation over a likely deal between Pfizer and India's biotechnology flag-bearer Biocon finally came true as the two companies announced a comprehensive global commercialization pact to bring to market a range of insulins including analogs like glargine, aspart and lispro
Piramal Deal Done, Abbott's India Plunge May Fetch Big Returns, But Integration Challenges, Growth Momentum Critical
MUMBAI - Piramal Healthcare Chairman Ajay Piramal redefined the valuation processes for Indian life science companies last week, when he sold his domestic business of predominantly 350 branded generic products to Illinois-based Abbott for $3.72 billion - a jaw-dropping price that is nine times the level of annual sales and 31 times that of earnings